Skip to content
Inciteful Med

Diagnosis & Your Tests: Confirming FSHD

Last updated:

Facioscapulohumeral dystrophy (FSHD) is confirmed through physical exams looking for asymmetrical weakness and highly specific genetic testing. The gold standard for diagnosis is a genetic test to measure your D4Z4 repeat count and identify the 4qA genetic haplotype.

Key Takeaways

  • • A definitive FSHD diagnosis requires both a clinical exam for asymmetrical weakness and molecular genetic testing.
  • • FSHD1 is confirmed by a D4Z4 repeat count of 1 to 10 units combined with a positive 4qA allele.
  • • FSHD2 testing checks for low methylation levels or SMCHD1 gene mutations when standard D4Z4 repeat counts fall in the normal range.
  • • Muscle MRIs help identify FSHD by revealing unique patterns, such as active inflammation and specific unaffected muscles like the hip flexor.
  • • Because FSHD can cause muscle inflammation, it is sometimes mistakenly diagnosed as polymyositis and incorrectly treated with steroids.

Confirming a diagnosis of FSHD requires a “detective work” approach that combines what a doctor sees during a physical exam with highly specific genetic and imaging tests. Because FSHD can mimic other conditions, getting the right tests—and interpreting them correctly—is essential for your long-term care.

The Diagnostic Blueprint

A definitive diagnosis typically rests on two pillars:

  1. Clinical Exam: A neurologist looks for the “hallmarks” of FSHD, such as asymmetry (weakness that is worse on one side) and the specific pattern of face and shoulder involvement [1][2].
  2. Molecular Genetic Testing: This is the gold standard used to confirm the diagnosis and determine whether you have FSHD1 or FSHD2 [3]. You can learn about how these two types differ in Biology & Genetics.

Modern Genetic Testing

The way FSHD is diagnosed genetically has evolved. While the Southern Blot was the traditional method for decades, it is complex and sometimes prone to technical errors [4][5].

  • Optical Genome Mapping (OGM): This modern technique is becoming the new standard. It is faster and more precise at measuring the D4Z4 repeat array and identifying the 4qA haplotype (the genetic “tail” required for the disease) [6][7].

How to Read Your Genetic Report: When looking at your test results, you don’t need a biology degree. Look for these key phrases:

  • For FSHD1: You are looking for a D4Z4 repeat count of 1 to 10 units AND a positive 4qA allele [5][8].
  • For FSHD2: If your repeat count is normal (11-20), your doctor should test for FSHD2. Look for mentions of hypomethylation (low methylation levels) or mutations in the SMCHD1 gene [9][10].

The Role of Muscle MRI

Magnetic Resonance Imaging (MRI) is a powerful tool for “seeing” the disease in action. It helps differentiate FSHD from other muscular dystrophies by looking at specific patterns of muscle damage.

  • STIR-Positive Lesions: “STIR” is a specific MRI setting that highlights edema (swelling) or active inflammation [11]. In FSHD, a muscle that looks “bright” on a STIR scan is often in an active state of disease before it is eventually replaced by fat [12].
  • Sparing Patterns: FSHD has a unique “signature” on MRI. For example, it often affects the trapezius (upper back) while leaving the iliopsoas (hip flexor) completely healthy—a pattern rarely seen in other dystrophies [13][14].

Avoiding Misdiagnosis

FSHD is frequently mistaken for other conditions, which can lead to ineffective treatments.

  • The “Inflammation Trap”: Because DUX4 triggers an immune response, a muscle biopsy of an FSHD patient often shows inflammation [15][16]. This can lead to a misdiagnosis of Polymyositis or other inflammatory myopathies. Patients may be incorrectly prescribed steroids, which do not treat the underlying cause of FSHD [17][18].
  • Limb-Girdle Muscular Dystrophy (LGMD): While both cause hip and shoulder weakness, LGMD is usually symmetrical, whereas FSHD is almost always asymmetrical [19][13].
  • Spinal Muscular Atrophy (SMA3): Adult-onset SMA can look like FSHD, but it generally lacks the facial weakness and “scapular winging” (protruding shoulder blades) typical of FSHD [20][21].

Genetic testing for the DUX4 pathway is the most reliable way to navigate these “look-alike” conditions and confirm your diagnosis [22][23].

Frequently Asked Questions

What is the gold standard test for diagnosing FSHD?
The gold standard for confirming an FSHD diagnosis is molecular genetic testing. Modern techniques like Optical Genome Mapping measure the D4Z4 repeat array and look for the specific 4qA genetic tail required for the disease.
How do I read my FSHD1 genetic test report?
A positive result for FSHD type 1 typically shows a D4Z4 repeat count between 1 and 10 units. Your report must also show a positive 4qA allele to confirm the disease.
What if my genetic test shows normal D4Z4 repeat counts?
If your repeat count is normal (usually 11 to 20 units) but you have symptoms, your doctor should test for FSHD2. This involves checking for low methylation levels or mutations in the SMCHD1 gene.
Why might my doctor order a muscle MRI for FSHD?
A muscle MRI helps differentiate FSHD from other muscular dystrophies by revealing unique patterns of muscle damage. It can spot active inflammation and show specific muscles that are characteristically affected or spared in FSHD.
Can FSHD be misdiagnosed as polymyositis?
Yes, FSHD is sometimes misdiagnosed as polymyositis because a muscle biopsy can show signs of inflammation. This can result in patients being incorrectly prescribed steroids, which do not treat the underlying cause of FSHD.

Questions for Your Doctor

  • • Does my genetic report confirm both a D4Z4 repeat count of 1-10 and the presence of the 4qA permissive haplotype?
  • • If my repeat count is in the 'borderline' range (8-10 units), have we tested for methylation or FSHD2-related mutations like SMCHD1?
  • • My biopsy showed signs of inflammation; can you explain how we have ruled out treatable conditions like polymyositis or myositis?
  • • On my muscle MRI, were there any STIR-positive areas, and does the pattern of muscle sparing (like the iliopsoas) support an FSHD diagnosis?

Questions for You

  • • Have I or my family members noticed that I'm the first one with these symptoms, or is there a history of 'drooping shoulders' or 'flat smiles' in my relatives?
  • • Was I ever prescribed steroids for 'muscle inflammation' that didn't seem to help my strength in the long run?
  • • Am I comfortable sharing my genetic report with a specialized neuromuscular center to ensure the interpretation is correct?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Updating the Clinical Picture of Facioscapulohumeral Muscular Dystrophy: Ramifications for Drug Development With Potential Solutions.

    Huml RA, Uspenskaya-Cadoz O, Dawson J, Slifer Z

    Therapeutic innovation & regulatory science 2020; (54(1)):144-150 doi:10.1007/s43441-019-00038-w.

    PMID: 32008231
  2. 2

    A case of type 1 facioscapulohumeral muscular dystrophy (FSHD) with restrictive ventilatory defect and congestive heart failure.

    Morimoto N, Morimoto M, Takahashi Y, et al.

    eNeurologicalSci 2020; (21()):100284 doi:10.1016/j.ensci.2020.100284.

    PMID: 33195829
  3. 3

    CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis.

    Rieken A, Bossler AD, Mathews KD, Moore SA

    Neurology 2021; (96(7)):e1054-e1062 doi:10.1212/WNL.0000000000011412.

    PMID: 33443126
  4. 4

    Evaluation of Optical Genome Mapping in Clinical Genetic Testing of Facioscapulohumeral Muscular Dystrophy.

    Kovanda A, Lovrečić L, Rudolf G, et al.

    Genes 2023; (14(12)) doi:10.3390/genes14122166.

    PMID: 38136988
  5. 5

    Analyzing Copy Number Variation Using Pulsed-Field Gel Electrophoresis: Providing a Genetic Diagnosis for FSHD1.

    Lemmers RJ

    Methods in molecular biology (Clifton, N.J.) 2017; (1492()):107-125 doi:10.1007/978-1-4939-6442-0_7.

    PMID: 27822859
  6. 6

    Validation of Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy.

    Stence AA, Thomason JG, Pruessner JA, et al.

    The Journal of molecular diagnostics : JMD 2021; (23(11)):1506-1514 doi:10.1016/j.jmoldx.2021.07.021.

    PMID: 34384893
  7. 7

    Clinical Application of Optical Genome Mapping for Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy.

    Shim Y, Seo J, Lee ST, et al.

    Annals of laboratory medicine 2024; (44(5)):437-445 doi:10.3343/alm.2023.0437.

    PMID: 38724225
  8. 8

    Genetic and epigenetic contributors to FSHD.

    Daxinger L, Tapscott SJ, van der Maarel SM

    Current opinion in genetics & development 2015; (33()):56-61.

    PMID: 26356006
  9. 9

    Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome.

    Renard D, Taieb G, Garibaldi M, et al.

    American journal of medical genetics. Part A 2018; (176(8)):1760-1763 doi:10.1002/ajmg.a.38843.

    PMID: 30055030
  10. 10

    Facioscapulohumeral Muscular Dystrophy.

    Statland JM, Tawil R

    Continuum (Minneapolis, Minn.) 2016; (22(6, Muscle and Neuromuscular Junction Disorders)):1916-1931 doi:10.1212/CON.0000000000000399.

    PMID: 27922500
  11. 11

    MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.

    Wang LH, Friedman SD, Shaw D, et al.

    Human molecular genetics 2019; (28(3)):476-486 doi:10.1093/hmg/ddy364.

    PMID: 30312408
  12. 12

    Natural history of facioscapulohumeral muscular dystrophy evaluated by multiparametric quantitative MRI: a prospective cohort study.

    Paoletti M, Monforte M, Barzaghi L, et al.

    Journal of neurology 2025; (272(4)):306 doi:10.1007/s00415-025-13062-8.

    PMID: 40172709
  13. 13

    Muscle MRI findings in facioscapulohumeral muscular dystrophy.

    Gerevini S, Scarlato M, Maggi L, et al.

    European radiology 2016; (26(3)):693-705 doi:10.1007/s00330-015-3890-1.

    PMID: 26115655
  14. 14

    Diagnostic magnetic resonance imaging biomarkers for facioscapulohumeral muscular dystrophy identified by machine learning.

    Monforte M, Bortolani S, Torchia E, et al.

    Journal of neurology 2022; (269(4)):2055-2063 doi:10.1007/s00415-021-10786-1.

    PMID: 34486074
  15. 15

    DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.

    Banerji CRS, Panamarova M, Zammit PS

    Human molecular genetics 2020; (29(14)):2285-2299 doi:10.1093/hmg/ddaa053.

    PMID: 32242220
  16. 16

    A human immune/muscle xenograft model of FSHD muscle pathology.

    Daman K, Yan J, Burzenski LM, et al.

    bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.11.17.567590.

    PMID: 38014123
  17. 17

    Potential pitfalls in the differential diagnosis of myositis versus hereditary myopathies.

    Glaubitz S, Zeng R, Hasanov K, et al.

    Clinical and experimental rheumatology 2026; (44(2)):304-312 doi:10.55563/clinexprheumatol/pqmby3.

    PMID: 41678169
  18. 18

    High prevalence of facioscapulohumeral muscular dystrophy (FSHD) and inflammatory myopathies association: Is there an interplay?

    Lauletta A, Allenbach Y, Béhin A, et al.

    Journal of the neurological sciences 2025; (470()):123400 doi:10.1016/j.jns.2025.123400.

    PMID: 39855012
  19. 19

    Muscle MRI in a Rare Case of Limb-Girdle Muscular Dystrophy 1B.

    Bokil SS, Durgi EC, Shah RN, et al.

    Cureus 2024; (16(10)):e72413 doi:10.7759/cureus.72413.

    PMID: 39588398
  20. 20

    Different profiles of upper limb function in four types of neuromuscular disorders.

    Bergsma A, Janssen MMHP, Geurts ACH, et al.

    Neuromuscular disorders : NMD 2017; (27(12)):1115-1122 doi:10.1016/j.nmd.2017.09.003.

    PMID: 29033278
  21. 21

    Evaluation of activities of daily living in patients with slowly progressive neuromuscular diseases.

    Bienias K, Ścibek J, Cegielska J, Kochanowski J

    Neurologia i neurochirurgia polska 2018; (52(2)):222-227 doi:10.1016/j.pjnns.2017.10.007.

    PMID: 29129380
  22. 22

    DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.

    Lim KRQ, Nguyen Q, Yokota T

    International journal of molecular sciences 2020; (21(3)) doi:10.3390/ijms21030729.

    PMID: 31979100
  23. 23

    What's in a name? The clinical features of facioscapulohumeral muscular dystrophy.

    Mul K, Lassche S, Voermans NC, et al.

    Practical neurology 2016; (16(3)):201-7 doi:10.1136/practneurol-2015-001353.

    PMID: 26862222

This page explains FSHD diagnostic tests and terminology for educational purposes. Your neurologist and genetic counselor are the best sources for interpreting your specific test results.

Stay up to date

Get notified when new research about Facioscapulohumeral dystrophy is published.

No spam. Unsubscribe anytime.